|Table of Contents|

Efficacy of TACE in combination with oral S-1 in patients with BCLC B stage hepatocellular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 22
Page:
3660-3664
Research Field:
Publishing date:

Info

Title:
Efficacy of TACE in combination with oral S-1 in patients with BCLC B stage hepatocellular carcinoma
Author(s):
Jiang Changchen1; Zhu Xixu1; Ding Difei2; Shen Zetian1
1.Department of Radiation Oncology,Nanjing General Hospital of Nanjing Military Region of PLA,Jiangsu Nanjing 210002,China;2.Department of Radiation Oncology,No.123 Hospital of PLA,Anhui Bengbu 233000,China.
Keywords:
BCLC B stage hepatocellular carcinoma; TACE; S-1; prognostic factor
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2017.22.029
Abstract:
Objective:To compare TACE alone and in combination with oral S-1 in the treatment of BCLC B stage hepatocellular carcinoma(HCC) and observe tumor response,TTP and adverse effects.Methods:According to different therapeutic regimens,fifty-four patients with intermediate HCC were enrolled into two groups:TACE plus S-1 (group A),TACE (group B).Based on " Up to 7" criteria and Child-Pugh score,four sub-stages of Barcelona Clinic Liver Cancer (BCLC) intermediate hepatocellular carcinoma (HCC) were proposed.Thus,patients of both groups were classified into four sub-stages as AB1-AB4 and BB1-BB4.The efficacy and TTP of each patient were detected.Results:In group A,the objective response rate(ORR) was 68.0%,the disease control rate(DCR) was 92.0% and the median time to progression(TTP) was 6.8 months.However,in group B,the ORR was 51.7%,the DCR was 79.3% and the TTP was 4.2 months.Patients in group A achieved better ORR and DCR,but neither achieve significant difference (P＞0.05).However,patients in the group A had a significantly longer mTTP than patients in group B(P=0.035).The result of subgroup analyses turned out that patients who exceed "Up to 7" showed a longer mTTP in group A when compared to group B.The toxicity was tolerable in both groups.Multivariate analysis showed that tumor response and "Up to 7" were independent prognostic factors of TTP.Conclusion:This study reported the efficacy and safety of TACE in combination with oral S-1 in BCLC B stage hepatocellular carcinoma.The results suggest that the combination therapy has better efficacy and the toxicity is tolerable.The combination management seems to be an appropriate option for the treatment of patients with intermediate hepatocellular carcinoma,especially whose target lesions exceed "Up to 7".

References:

［1］Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methords and major patterns in GLOBOCAN 2012［J］.Int J Cancer,2015,136(5):E359-386.
［2］Llovet JM,Bruix J.Systematic review of randomized trials for unreseetable hepatocellular carcinoma:Chemoembolization improves survival［J］.Hepatology,2003,37(2):429-442.
［3］Locm,Nganh,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma ［J］.Hepatology,2002,35(5):1164-1171.
［4］Junji Furuse,Takuji Okusaka.Phase I/II study of the pharmacokinetics,safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma［J］.Cancer,2010,101(12):2606-2611.
［5］Mazzaferro V，Llovet JM，Miceli R，et al．Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria：a retrospective，exploratory analysis［J］． Lancet Oncol，2009，10(1)：35-43．
［6］Llovet JM，Realmi，Montaiax,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial［J］.Lancet,2002,359(9319):1734-1739.
［7］Sergio A,Cristofori C,Cardin R,et al.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC):the role of angiogenesis and invasiveness［J］.Am J Gastroenterol,2008,103(4):914-921.
［8］Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind,placebo-controlled trial［J］.Lancet Oncol,2009,10:25-34.
［9］Forner A,Llovet JM,Bruix J.Hepatocellular carcinoma［J］.Lancet,2012,379(9822):1245-1255.
［10］Yang P,Liang MH,Zhang YX,et al.Clinical application of a combination therapy Lentinan,multi-electrode RFA and TACE in HCC ［J］.Adv Ther,2008,25(8):787-794.
［11］Fan Wenzhe,Yang Jianyong,Lv Mingde,et al.Transcatheter arterial chemoembolization plus percutaneous thermal ablation in large hepatocellular carcinoma:clinical observation of efficacy and predictors of prognostic factors［J］.National Medical J China,2011,91(31):2190-2194.［范文哲,杨建勇,吕明德,等.TACE 联合经皮热消融治疗大肝癌的疗效及预后分析［J］.中华医学杂志,2011,91(31):2190-2194.］
［12］Song DS,Song MJ.A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis［J］.J Gastroenterol,2015,50(4):445-454.
［13］Ruzzenente A,Capra F,Pachera S,et al.Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients［J］.J Gastrointest Surg,2009,13(7):1313-1320.
［14］Chen FG,Wang JJ,Xue Q,et al.Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1［J］.Chin J Hepatol,2009,17(9):665-668.
［15］Kawamoto K,Eguchi H.A case of successful surgical resection followed by S-1 administration for hepatocellular carcinoma with lung metastases and a tumor thrombus into right atrium［J］.Gan To Kagaku Ryoho,2011,38(12):2490-2492.
［16］Yamashita T,Arai K.A case report of S-1 monotherapy for advanced hepatocellular carcinoma［J］.Gan To Kagaku Ryoho,2012,39(9):1435-1437.

Memo

Memo:
-
Last Update: 1900-01-01